Novavax to Make Multiple Presentations at RSV Vaccines for the World
(Thomson Reuters ONE) -
GAITHERSBURG, Md., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced that Novavax representatives will be making multiple
oral presentations at the RSV Vaccines for the World conference, November
18-20, 2015 in La Jolla, California.
Poster, presentation titles and presenters are listed below:
* "Biophysical Characterization of an RSV Nanoparticle Vaccine."
Oleg Borisov, Ph.D., Director, Analytical Development, Novavax, Inc.
* "Randomized Phase 2 Trial of an RSV F Nanoparticle Vaccine in the Elderly:
Epidemiology and Efficacy."
Vivek Shinde, M.D., Director, Clinical Development, Novavax, Inc.
* "Phase 2 Trial of an RSV F Nanoparticle Vaccine in Pregnant Women Towards
Maternal Immunization."
Allison August, M.D., Director, Clinical Research, Novavax, Inc.
* "Sera Derived from Immunization with a Recombinant RSV F-protein
Nanoparticle Vaccine Obtained from Cotton Rats and Women of Child-bearing
Age Contains Antibodies Competitive with Neutralizing Monoclonals Against
Multiple Epitopes."
Hanxin Lu, Ph.D., Senior Scientist, Novavax, Inc.
The final conference program is available
at: http://www.meetingsmanagement.co.uk/images/stories/pdf/rsvvw-2015-
leaflet.pdf
About RSV
RSV is a major respiratory pathogen in infants, children, and adults. RSV
infections in adults represent re-infections and are generally mild to moderate
in severity, except in persons with high-risk conditions including the elderly
and adults with underlying chronic cardiac or pulmonary disease. It is estimated
that 2.4 million adults 65 years of age or older are infected with RSV annually
in the U.S. leading to as many as 900,000 medical interventions and 14,000
deaths each year.(1-5) RSV is the most common cause of lower respiratory tract
infections and the leading viral cause of severe lower respiratory tract disease
in infants and young children worldwide, with estimated annual infection and
mortality rates of 64 million and 160,000, respectively.(6) In the US, RSV is
the leading cause of hospitalization of infants.(7) Currently, there is no
approved RSV vaccine available.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases. Our
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines. Additional information about Novavax is available
on the Company's website, novavax.com.
References:
1. Falsey, A.R. et al. Respiratory syncytial virus infection in elderly and
high-risk adults. N Engl J Med, 2005; 352:1749-59; extrapolated to 2015
census population.
2. Falsey, A.R. et al. Respiratory Syncytial Virus and Influenza A Infections
In The Hospital Elderly. J. Infect Dis,1995;172:389-94
3. CDC: http://www.cdc.gov/rsv/research/us-surveillance.html
4. Widmer, K. et al. Rates of Hospitalizations for Respiratory Syncytial Virus,
Human Metapneumovirus and Influenza Virus in Older Adults. J Infect Dis,
2012; 206: 56-62.
5. Widmer, K. et al. Respiratory Syncytial Virus & Human Metapneumovirus-
Associated Emergency Department and Hospital Burden in Adults. Influenza
Other Respir Viruses, 2014; 8(3): 347-352.
6. Nair, H. et al. Global burden of acute lower respiratory infections due to
respiratory syncytial virus in young children: a systematic review and meta-
analysis. Lancet, 2010; 375: 1545-1555.
7. Hall, C.B. et al. Respiratory Syncytial Virus-Associated hospitalizations
Among Children Less Than 24 Months of Age. Pediatrics, 2013; 132(2): E341-
348.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
ir(at)novavax.com
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull(at)russopartnersllc.com
todd.davenport(at)russopartnersllc.com
212-845-4271
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novavax, Inc. via GlobeNewswire
[HUG#1966833]
Unternehmensinformation / Kurzprofil:
Datum: 16.11.2015 - 22:05 Uhr
Sprache: Deutsch
News-ID 435034
Anzahl Zeichen: 5504
contact information:
Town:
Maryland
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novavax to Make Multiple Presentations at RSV Vaccines for the World"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
